Compugen Ltd. (CGEN)

NASDAQ: CGEN · IEX Real-Time Price · USD
2.27
+0.16 (7.58%)
Jul 7, 2022 12:59 PM EDT - Market open
7.58%
Market Cap 196.26M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 86.46M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 384,842
Open 2.11
Previous Close 2.11
Day's Range 2.09 - 2.28
52-Week Range 1.55 - 7.84
Beta 2.43
Analysts Buy
Price Target 11.99 (+428.2%)
Earnings Date Jul 27, 2022

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that ... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Aug 11, 2000
Employees 73
Stock Exchange NASDAQ
Ticker Symbol CGEN
Full Company Profile

Financial Performance

In 2021, Compugen's revenue was $6.00 million, an increase of 200.00% compared to the previous year's $2.00 million. Losses were -$34.20 million, 15.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CGEN stock is "Buy." The 12-month stock price forecast is 11.99, which is an increase of 428.19% from the latest price.

Price Target
$11.99
(428.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Compugen to Present at Upcoming Industry Conferences

HOLON, ISRAEL , June 27, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that members of...

Compugen to Present at Upcoming Investor Conferences

HOLON, Israel , June 1, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management ...

Compugen Reports First Quarter 2022 Results

Triple blockade of PVRIG/TIGIT/PD-1 may be required to optimize clinical responses COM701, a unique check point inhibitor, with potential to recruit additional T cells to the TME COM902 has the potentia...

Compugen Announces CFO Departure

HOLON, Israel , May 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Mr.

Compugen to Release First Quarter 2022 on Monday, May 16, 2022

HOLON, Israel , May 2, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the Company ...

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics to Gain In-Depth Understanding of th...

HOLON, Israel, March 21, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, to...

Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keyston...

HOLON, Israel , March 14, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has be...

Compugen to Present at the Oppenheimer 32nd Annual Global Healthcare Conference

HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management ...

Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise for Treatment of Multiple Myeloma

HOLON, Israel, March 9, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN),("Compugen," the "Company"), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, toda...

5 Best Penny Stocks Under $5 To Buy According To Analysts Right Now

Today we look at five penny stocks to buy according to some of Wall Street's analyst firms. The post 5 Best Penny Stocks Under $5 To Buy According To Analysts Right Now appeared first on Penny Stocks to...

Other symbols: APPHBITFGSATGFAI

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

HOLON, Israel , Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announ...

Compugen Reports Fourth Quarter and Full Year 2021 Results

HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today rep...

Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022

HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company wil...

7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings

Cathie Wood stocks to watch right now. The post 7 Penny Stocks To Buy Based On Cathie Wood's ARK Invest Holdings appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Compugen to Present at the 11th Annual SVB Leerink Global Healthcare Conference

HOLON, Israel, Feb. 9, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that management will ...

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with ant...

HOLON, Israel, Jan. 18, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ-GM: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the United S...

Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM...

HOLON, Israel, Dec. 9, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of p...

3 Penny Stocks Cathie Wood's ARK Invest Bought In 2021, Will You?

3 penny stocks attracting attention from ARK Invest family of funds. The post 3 Penny Stocks Cathie Wood's ARK Invest Bought In 2021, Will You?

Other symbols: AQBNNDM

Why Compugen Stock Got Slammed Today

A price cut from an analyst had some traders hitting the sell button.

Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment

Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.

Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Compared to TIGIT and PD-1 as a ...

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of ...

Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of COM902 a High Affinity Anti-T...

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of ...

Compugen Reports Third Quarter 2021 Results

- COM701, Opdivo® and BMS-986207, triple combination dose escalation Phase 1/2 data being presented at 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) clears the path to studies in...

Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 with Opdivo® and BMS-986207 (Ant...

HOLON, Israel, Nov. 12, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of ...